HRT explained: benefits, risks and options for menopause

Written and evidence-checked by the VeriNourish Editorial Team against 8 named sources listed below. No licensed clinician reviews this content.

HRT is the most effective treatment for hot flashes and night sweats, and for many women it is the single change that makes the rest of menopause manageable. It also carries risks, and almost all of them depend on what you take rather than on HRT as a category. A tablet and a patch differ on blood clots. Estrogen alone and estrogen with a progestogen differ on breast cancer.

This guide follows NICE, the UK guideline body, alongside The Menopause Society's 2022 position statement for North America. It is written to prepare you for a conversation with a doctor rather than to pick a product.

What HRT treats

NICE recommends offering HRT for vasomotor symptoms, the hot flushes and sweats that most women mean when they say menopause symptoms (NICE NG23). The Menopause Society reaches the same conclusion and adds the genitourinary syndrome of menopause, the vaginal and urinary symptoms, along with prevention of bone loss and fracture (Menopause, 2022).

Three more points are worth having straight before an appointment.

Mood. NICE suggests considering HRT for depressive symptoms that do not meet the criteria for a diagnosis of depression and that start around the same time as other menopause symptoms. Diagnosed depression is assessed and treated in its own right. Menopause-specific cognitive behavioral therapy is an option for those symptoms too (NICE NG23).

Bones. Fracture risk falls while you take HRT, and that benefit decreases once treatment stops, though it may last longer in women who took it for longer. NICE also asks clinicians to raise bone health at review appointments and to explain why muscle mass and strength are worth maintaining through activity (NICE NG23). Our guides to osteoporosis and bone care and strength training cover the rest.

Prevention is not an indication. NICE says HRT should not be offered to prevent cardiovascular disease, or to prevent dementia (NICE NG23). Symptom relief is the reason to take it.

If hot flashes and night sweats are what wake you, treating them is also the most direct route to better sleep. Mood swings and brain fog have their own guides, because they have causes beyond hormones.

The forms, and what each one is for

The first question is whether you need treatment that reaches the whole body or treatment that works where the symptom is.

Form	What it treats	What to know
Tablets, taken by mouth	Hot flashes, night sweats and other whole-body symptoms	Clot risk is increased with oral HRT, and stroke risk rises with oral estrogen
Patches, gels and sprays, absorbed through the skin	The same whole-body symptoms	NICE reports clot risk is not increased with transdermal HRT, and stroke risk is unlikely to increase
Low-dose vaginal creams, tablets, pessaries and rings	Vaginal dryness, discomfort and some urinary symptoms	Absorbed locally, with minimal amounts reaching the bloodstream. They do not treat hot flashes, and they can be used alongside systemic HRT

Sources for the table: NICE NG23 and the NHS.

Most estrogen medicines now use estradiol, which is identical to the estrogen your own body makes. NICE advises using the lowest effective dose (NICE NG23). Our guide to vaginal dryness covers the local treatments in more detail, including moisturizers and lubricants.

When a progestogen is part of it

If you still have a womb and you take systemic estrogen, you also need a progestogen. Estrogen on its own raises the risk of cancer of the womb lining, and that applies to patches and gels as much as to tablets, so the route does not change the need (NICE NG23). After a total hysterectomy, estrogen-only HRT is what NICE recommends offering.

The progestogen can come as a separate medicine, such as micronized progesterone, as a combined product, or from a hormonal intrauterine system, which is useful if you also want contraception or have heavy periods (NHS). Sequential combined HRT is used while you are still having periods and continuous combined HRT after they stop. That choice also affects the womb lining: NICE reports that continuous combined HRT decreases endometrial cancer risk, while sequential combined HRT may slightly increase it, more so with longer use, fewer progestogen days per cycle and a higher estrogen dose.

Low-dose vaginal estrogen is the exception. A progestogen is generally not needed with it, though trial data on endometrial safety beyond a year are lacking, and any bleeding after menopause still needs to be checked (Menopause, 2022). Our guides to estrogen and progesterone explain what each hormone does.

The risks, outcome by outcome

The lines below are NICE's summary for women with no personal history of the condition in question (NICE NG23). A personal history of breast, endometrial or ovarian cancer, or of stroke, needs a specialist's answer instead.

Outcome	Combined HRT	Estrogen-only HRT
Blood clots	Increased with tablets, not increased with patches, gels or sprays	Same pattern: oral increases it, transdermal does not
Stroke	Increased with oral estrogen, rising with dose, longer use and older age at starting; unlikely to increase with transdermal	Increased with oral, unlikely to increase with transdermal
Breast cancer	Increased, more so the longer it is used; the excess falls after stopping but persists for at least 10 years	Very little or no increase
Womb lining	Decreased with continuous combined; may slightly increase with sequential	Increased in anyone with a uterus, which is why it is used after hysterectomy
Ovarian cancer	Very slight increase	Very slight increase after 5 years, rising with duration
Coronary heart disease	No increase	No increase
Dementia	Might increase if started at 65 or over	Unlikely to increase
Fracture	Reduced while you take it	Reduced while you take it
Life expectancy	Unlikely to change	Unlikely to change

Two details inside that table get misquoted often. There is not enough evidence to say whether micronized progesterone carries a different breast cancer risk from other progestogens, so a "body-identical" label is not a safety claim. And the breast cancer excess with combined HRT is higher while you are taking it than after you stop, which is why the conversation is about duration as well as type.

NICE publishes a discussion aid that turns these statements into numbers of cases per 1,000 women over 5 and 10 years. Ask for it, because a relative increase in a rare outcome sounds different once you see the absolute figures.

Much of the older fear traces to the Women's Health Initiative, which tested one route and one combination: oral conjugated equine estrogens with medroxyprogesterone acetate, with few participants under 60 or within 10 years of menopause who had bothersome symptoms (Menopause, 2022). Its results do not transfer cleanly to a 52-year-old starting an estradiol patch.

Who it suits, and who needs a specialist first

For women under 60, or within 10 years of menopause, with no contraindications, The Menopause Society puts the balance of benefits and risks in favor of treatment for bothersome hot flashes and for preventing bone loss. Starting more than 10 years after menopause, or after 60, is less favorable, because the underlying risks of heart disease, stroke, clots and dementia rise with age. Continuing treatment you are already on is a separate decision from starting it: hormone therapy does not need to be stopped routinely at 60 or 65 (Menopause, 2022).

Tell whoever prescribes it if you have had breast cancer, are being tested for it or are considered high risk from family history; have had another cancer; have vaginal bleeding with no known cause; have had a blood clot or have thrombophilia; have had angina or a heart attack; have liver problems, diabetes, migraines or high blood pressure; or could be pregnant (NHS). Untreated high blood pressure has to be controlled before HRT starts, and a history of clots may mean patches or gels rather than tablets (NHS).

NICE adds a few routes that should not run through a general appointment alone (NICE NG23):

At increased clot risk, including a BMI over 30, transdermal HRT is preferred to tablets; at high risk, such as a strong family history or hereditary thrombophilia, assessment by a hematologist comes before HRT.
With a personal history of coronary heart disease or stroke, the discussion belongs with a healthcare professional who has expertise in menopause.
After breast cancer, non-hormonal moisturizers and lubricants come first for vaginal symptoms; vaginal estrogen may be considered if symptoms continue, and anyone taking an aromatase inhibitor needs their breast cancer specialist involved.
With premature ovarian insufficiency, under 40, treatment is offered as HRT or a combined hormonal contraceptive and continued until at least the usual age of menopause, unless it is contraindicated. Risk figures from older postmenopausal groups do not apply.

Side effects, bleeding and the review schedule

Headaches, breast tenderness, nausea and mood changes are common in the first weeks and usually settle as your body adjusts. Speak to your doctor if they last or bother you, since the dose or the type can be changed (NHS). There is little evidence that most types of HRT cause weight gain, and weight often changes around menopause with or without it (NHS).

HRT can take up to 3 months to work fully (NHS). NICE suggests reviewing each treatment at 3 months for how well it works and how well you tolerate it, then once a year, with an earlier review if it is not working or side effects continue, and referral to a menopause specialist if that does not fix it (NICE NG23).

Bleeding has its own rules. NICE describes vaginal bleeding as a common side effect of systemic HRT in the first 3 months, asked about at the 3-month review, and advises seeking medical help promptly for bleeding after that. The NHS puts the settling-in window at 3 to 6 months and says to talk to your doctor about heavy or unexpected bleeding after 6 months of treatment, and about any vaginal bleeding at all if you have had a hysterectomy. The British Menopause Society asks clinicians to investigate sooner when endometrial cancer risk factors are present, naming a BMI of 40 or over, Lynch syndrome and Cowden syndrome as major factors and a BMI of 30 to 39, diabetes and PMOS, formerly PCOS, as minor ones (BMS).

Some symptoms need help the same day rather than at a review. Call 999, or your local emergency number, for chest pain with breathlessness, severe difficulty breathing, pain in your chest or upper back, a very fast heartbeat, or signs of a stroke such as a dropped face, arm weakness or difficulty speaking. Ask for an urgent appointment or call 111 for sudden breathlessness that is not severe, coughing up blood, or pain, redness or swelling in one calf, which can be a clot in the leg (NHS). Report a new breast lump or a change in your breasts, and keep going to breast screening appointments.

What the 2026 US label change did and did not do

On 12 February 2026 the FDA approved labeling changes for six menopausal hormone products, removing the statements about cardiovascular disease, breast cancer and probable dementia from the boxed warning (FDA).

Read what that covers. It is a US labeling decision about specific products. Individual labels still carry their own warnings: the February 2026 prescribing information for one estradiol gel keeps a boxed warning about endometrial cancer with unopposed estrogen in a woman with a uterus, along with contraindications including known thrombophilic disorders and liver disease (FDA label, 2026). NICE's summary of benefits and risks, which this page uses, is unchanged. A headline saying the warnings were removed is not a reason to start or stop treatment.

If HRT is not for you

You can treat the symptoms without hormones. NICE suggests menopause-specific cognitive behavioral therapy for hot flushes and sweats, either alongside HRT or instead of it, and as an option for depressive symptoms that come with them. It also advises against routinely offering SSRIs, SNRIs or clonidine as a first-line treatment for hot flushes alone (NICE NG23). Moisturizers and lubricants help vaginal symptoms, and staying strong through activity supports bone and muscle.

One caution on what gets sold as a gentler alternative: NICE says the efficacy and safety of unregulated hormone preparations are unknown, and that the quality and purity of what is in them may be unknown too. A regulated estradiol patch or micronized progesterone capsule is a different thing from a compounded mixture marketed as bioidentical.

What to take to the appointment

The symptoms you most want to change, and how they affect your week.
Whether you still have a womb, and whether you still have periods.
Your history of clots, heart disease, stroke, cancer, liver problems, migraines and blood pressure, plus your family history of breast cancer and clots.
Every medicine and supplement you take.
What contraception you use, since HRT is not one. The NHS advises contraception until 2 years after your last period if you are under 50, or 1 year after 50.

Useful questions: do I need whole-body treatment, local treatment or both; what protects my womb lining; what do the absolute numbers look like for me; which side effects should I report and how fast; and when is the review.

When to see a doctor

See a doctor if menopause symptoms are affecting your life, if you want the risks explained for your own history, or if you tried HRT and it did not suit you, since the type, dose and route can be changed rather than abandoned quietly. Our guide to menopause covers what else changes and when to seek help.

Frequently asked questions

What is HRT?

Hormone replacement therapy replaces the estrogen that falls at menopause, with a progestogen added for anyone who still has a womb. NICE recommends offering it for hot flashes and night sweats, and The Menopause Society calls it the most effective treatment for those symptoms and for vaginal and urinary symptoms. It also reduces fracture risk while you take it.

Do I still need a progestogen if I use a patch or gel?

Yes, if you have a womb. NICE says endometrial cancer risk rises with estrogen-only HRT in people with a uterus, with patches and gels as well as tablets, which is why combined HRT is offered to anyone who has not had a hysterectomy. Low-dose vaginal estrogen is the exception: a progestogen is generally not needed with it.

Is HRT safe? What are the risks?

The risks depend on what you take and how. NICE reports that clot risk is increased with oral HRT and not increased with transdermal estrogen, that stroke risk rises with oral estrogen and is unlikely to rise with patches or gels, and that combined HRT raises breast cancer risk with longer use while estrogen-only HRT shows very little or no increase. Coronary heart disease risk does not increase, and overall life expectancy is unlikely to change.

Does HRT cause weight gain?

There is little evidence that most types of HRT make you put on weight, according to the NHS. Weight often changes around menopause and with age whether or not you take HRT. HRT is not a weight-loss treatment, and bloating or fluid retention can happen while you take it.

How long does HRT take to work?

It can take up to 3 months to work fully, though some symptoms ease sooner. NICE suggests a review at 3 months and then once a year, with an earlier review if the treatment is not working or side effects are troublesome. Do not wait for a scheduled review if you have warning signs such as chest pain, breathlessness or leg swelling.

Is HRT a contraceptive?

No. You can still get pregnant while taking it. The NHS advises using contraception until 2 years after your last period if you are under 50, or for 1 year after the age of 50.

Is there an age at which I have to stop?

No fixed one. The Menopause Society's 2022 statement says hormone therapy does not need to be routinely discontinued at 60 or 65, and that longer use should be for a documented reason with regular reassessment. Starting HRT for the first time after 60, or more than 10 years after menopause, has a less favorable balance of benefits and risks than starting earlier.

Who might not be suitable for HRT?

Tell your doctor if you have had breast cancer or are being tested for it, have had any other cancer, have unexplained vaginal bleeding, have had a blood clot or have thrombophilia, have had angina or a heart attack, have liver problems, untreated high blood pressure, diabetes or migraines. Some of these rule out systemic HRT, others change the route or mean a specialist decides. Untreated high blood pressure has to be controlled first.

References

Menopause: identification and management (NICE guideline NG23) · NICE, November 2024, via NCBI Bookshelf
The 2022 hormone therapy position statement of The North American Menopause Society · Menopause, 2022;29(7):767-794
About hormone replacement therapy (HRT) · NHS
Side effects of estrogen tablets, patches, gel and spray · NHS
Common questions about estrogen tablets, patches, gel and spray · NHS
Side effects of hormone replacement therapy (HRT) · NHS
Management of unscheduled bleeding on hormone replacement therapy · British Menopause Society
FDA approves labeling changes to menopausal hormone therapy products · US Food and Drug Administration, 12 February 2026